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Clinical Infectious Diseases
SUPPLEMENT ARTICLE

Safety of Induced Sputum Collection in Children
Hospitalized With Severe or Very Severe Pneumonia
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Background. Induced sputum (IS) may provide diagnostic information about the etiology of pneumonia. The safety of this
procedure across a heterogeneous population with severe pneumonia in low- and middle-income countries has not been described.
Methods. IS specimens were obtained as part a 7-country study of the etiology of severe and very severe pneumonia in hospitalized children <5 years of age. Rigorous clinical monitoring was done before, during, and after the procedure to record oxygen
requirement, oxygen saturation, respiratory rate, consciousness level, and other evidence of clinical deterioration. Criteria for IS contraindications were predefined and serious adverse events (SAEs) were reported to ethics committees and a central safety monitor.
Results. A total of 4653 IS procedures were done among 3802 children. Thirteen SAEs were reported in relation to collection of
IS, or 0.34% of children with at least 1 IS specimen collected (95% confidence interval, 0.15%–0.53%). A drop in oxygen saturation
that required supplemental oxygen was the most common SAE. One child died after feeding was reinitiated 2 hours after undergoing
sputum induction; this death was categorized as “possibly related” to the procedure.
Conclusions. The overall frequency of SAEs was very low, and the nature of most SAEs was manageable, demonstrating a lowrisk safety profile for IS collection even among severely ill children in low-income-country settings. Healthcare providers should
monitor oxygen saturation and requirements during and after IS collection, and assess patients prior to reinitiating feeding after the
IS procedure, to ensure patient safety.
Keywords. PERCH; induced sputum; very severe pneumonia; severe pneumonia; safety.

Induced sputum (IS) examination in immunocompromised children for Pneumocystis jirovecii and for suspected
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Mycobacterium tuberculosis is the standard of care [1–4]. Given
its utility in this subset of children, there has been increased
interest in its use for pneumonia diagnosis in children more
generally [5]. While several small studies have found that the
IS procedure was well tolerated in children, and produced quality specimens for pneumonia pathogen identification [2–4, 6],
there have been no large-scale studies evaluating the safety of
this procedure in children with severe and very severe pneumonia. We describe the safety profile of the IS procedure performed
at 9 sites in 7 countries, among a heterogeneous population of
children 1–59 months of age hospitalized with severe and very
severe pneumonia.
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METHODS

IS specimens were collected from cases enrolled in the Pneumonia
Etiology Research for Child Health (PERCH) study, a 9-site,
7-country case-control study of World Health Organization
(WHO)–defined severe or very severe pneumonia in hospitalized children and community controls aged 1–59 months, to estimate the causes of pneumonia in children. The study design and
methods have been described elsewhere, and training materials
as well as study documents are publically available describing
the standardized methods that were used across heterogeneous
settings and populations [7–10]. The PERCH study protocol
was approved by the institutional review board or ethical review
committee at each of the study site institutions and at the Johns
Hopkins Bloomberg School of Public Health. Parents or guardians of all participants provided written informed consent.
Protocol Development

During the PERCH study design phase, experts in pediatric
respiratory disease were asked to synthesize the evidence on
the safety and utility of IS collection in children [5]. After considering the risks and benefits, 16 pediatric pneumonia experts
endorsed the collection of IS in PERCH, particularly for detection of tuberculosis and pneumocystis pneumonia. These same
experts also recommended that IS be obtained from all PERCH
cases using nebulization with hypertonic saline, excepting those
children with a clear contraindication, such as hypoxia [5].
Of the 9 sites (in 7 countries) selected to be part of PERCH
in 2010, 2 (Kenya and South Africa) were already collecting IS
specimens as part of routine clinical care from children hospitalized with pneumonia, and 1 site solely for study purposes (The
Gambia). A standardized operating procedure (SOP) based on
the techniques used by these sites was developed and agreed
upon by all investigators [11]. To facilitate cross-site collaboration and standardization of methods, teams without experience
in IS collection were trained by experienced study investigators
from sites using the procedure routinely. Because 6 of the 9 sites
initiated sputum collection as a new study procedure, we implemented standardized clinical monitoring for all sites to assess the
procedure safety and ensure the safety of study participants [12].
IS Procedure

The IS procedure is described in detail in accompanying papers
[13, 14]. In brief, at the time of IS collection, a nebulized β-agonist was administered to enrolled PERCH cases, followed by
inhaled nebulized 5% hypertonic saline (to induce expectoration). Sputum was collected using a sterile catheter passed
through the nose and suction was applied to aspirate the contents of the posterior nasopharynx. Without suction, the catheter was then removed from the nose and flushed with sterile
normal saline into a closed mucous trap. The specimen was collected within 24 hours of admission whenever possible, among
children without contraindications (see below).
S302 • CID 2017:64 (Suppl 3) • DeLuca et al

In South Africa, >1 IS specimen was routinely collected from
each child to enhance the detection of M. tuberculosis. At other
sites, an additional IS specimen for tuberculosis diagnosis was
collected at the discretion of the clinical provider. Multiple
specimens from the same child were not pooled, as the second
specimen was collected >24 hours after the first for children in
whom tuberculosis was suspected.
Contraindications to collection of IS included oxygen saturation
<92% on supplemental oxygen, inability to protect airway, severe
bronchospasm, seizure within the preceding 24 hours, or deemed
inadvisable by the treating physician. Children who underwent
IS collection were closely monitored before, during, and after the
procedure. Clinical measures including oxygen saturation and oxygen requirement, respiratory rate, and consciousness level (using
the alert, voice, pain, unresponsive [AVPU] scale) were recorded
immediately before and after the IS procedure, as well as at 30
minutes, 2 hours, and 4 hours following the procedure. Criteria for
stopping the procedure were oxygen saturation ≤88% for >60 seconds or oxygen saturation of 89%–91% for >60 seconds despite an
increase in supplemental oxygen. If after a period of stabilization
or rest the child’s respiratory status improved to their preprocedure
baseline status, IS collection was resumed when oxygen saturation was ≥92% for 5 minutes or more. If the oxygen requirement
remained greater than the requirement prior to the procedure,
the IS procedure was only restarted after careful evaluation of the
child’s clinical status and stability, noting possible disease progression and the magnitude of change in oxygen requirement.
Severe Adverse Event Reporting

In collaboration with the ethical review boards that approved
the study, 4 criteria were established for categorizing a change in
clinical status as a serious adverse event (SAE) in PERCH cases
undergoing IS specimen collection. These 4 conditions were
reported as SAEs if they occurred any time between the initiating the procedure and 4 hours postprocedure: (1) death (for any
reason); (2) drop in oxygen saturation by ≥5% for at least 15 minutes; (3) new onset of unconsciousness or prostration; and (4)
new requirement for bronchodilator or increased frequency of
bronchodilator treatment. Each site assigned an independent clinician to be the site safety monitor for the study, and when an SAE
occurred, the study staff completed a report describing the event.
The site safety monitor was responsible for reviewing each SAE
report and determining whether the event could be attributed to
a specific procedure. Relatedness was assigned as definitely, probably, possibly, and probably not. Reports were then submitted for
review to the PERCH study-wide safety monitor, a physician
who had no other investigator role in the PERCH study, and were
forwarded to the Johns Hopkins University Institutional Review
Board (IRB) and the site ethical review board(s).
The above monitoring and SAE reporting criteria were developed to safeguard children with severe respiratory illness from
developing complications due to a study procedure. At least 1

study investigator from each site (usually the primary study clinician) participated in a PERCH Clinical and Epidemiology
Working Group that reviewed the contraindications for IS collection, the criteria for defining SAEs, and the SAEs as they occurred.
Statistical Analysis

We performed a descriptive analysis, calculating frequencies
for categorical variables and medians and interquartile ranges
for continuous variables, to compare the safety parameters at
the various clinical monitoring time points. Given that the
PERCH guidelines specified collection of 1 IS specimen and
Table 1.

that children from whom a second IS specimen was collected
may have differed from those with 1 IS, risks were calculated
separately for the first IS and the second IS. Also, separately
for the first and second IS, McNemar χ2 test was used to assess
differences in oxygen requirement, saturation, and respiratory
rate before and after the IS procedure.
RESULTS

Over the course of a 24-month enrollment period at each
site, 3802 of 4232 (90%) enrolled PERCH patients underwent

Characteristics of Pneumonia Etiology Research for Child Health (PERCH) Study Cases With Induced Sputum Collection

Characteristic

Children With
1 IS Specimen
(n = 2951)

Children With
>1 IS Specimen
(n = 851)a

All Children
With IS Specimen
(n = 3802)

All IS Specimens
(N = 4653)

Age
1 mo to <6 mo

1139 (38.6)

410 (48.2)

1549 (40.7)

1959 (42.1)

6–11 mo

649 (22.0)

212 (24.9)

861 (22.6)

1073 (23.1)

12–23 mo

705 (23.9)

156 (18.3)

861 (22.6)

1017 (21.9)

24–59 mo

458 (15.5)

73 (8.6)

531 (14.0)

604 (13.0)

2114 (71.6)

599 (70.4)

2713 (71.4)

3312 (71.2)

837 (28.4)

252 (29.6)

1089 (28.6)

1341 (28.8)

Female

1210 (41.0)

385 (45.2)

1595 (42.0)

1980 (42.6)

Male

1741 (59.0)

466 (54.8)

2207 (58.0)

2673 (57.4)

Severity
Severe
Very severe
Sex

HIV statusb
Positive

112 (3.8)

93 (10.9)

205 (5.4)

298 (6.4)

Negative

2527 (85.6)

751 (88.2)

3278 (86.2)

4029 (86.6)

Unknown

312 (10.6)

7 (0.8)

319 (8.4)

326 (7.0)

HIV exposurec
Exposed
Unexposed
Unknown

267 (9.0)

353 (41.5)

620 (16.3)

973 (20.9)

2370 (80.3)

460 (54.1)

2830 (74.4)

3290 (70.7)

314 (10.6)

38 (4.5)

352 (9.3)

390 (8.4)

Receiving supplemental oxygen
At admission

500 (16.9)

702 (82.5)a

1202 (31.6)

1904 (40.9)

Everd

808 (27.4)

767 (90.1)

1576 (41.4)

2343 (50.4)

Immediately prior to IS

524 (17.8)

577 (67.8)e

1101 (29.0)

1580 (34.0)

Kilifi, Kenya

550 (18.6)

44 (5.2)

594 (15.6)

638 (13.7)

Basse, The Gambia

588 (19.9)

8 (0.9)

596 (15.7)

604 (13.0)

Bamako, Mali

544 (18.4)

0 (0.0)

544 (14.3)

544 (11.7)

Lusaka, Zambia

517 (17.5)

1 (0.1)

518 (13.6)

519 (11.2)

56 (1.9)

785 (92.2)

841 (22.1)

1626 (34.9)

Country/study site

Soweto, South Africa
Nakhon Phanom and Sa Kaeo, Thailand

190 (6.4)

Dhaka and Matlab, Bangladesh

506 (17.2)

1 (0.1)
12 (1.4)

191 (5.0)

192 (4.1)

518 (13.6)

530 (11.4)

Data are presented as No. (%).
Abbreviations: HIV, human immunodeficiency virus; IS, induced sputum.
a

Among children with >1 IS, 92% were from the South African site where it was standard of care to place children with pneumonia on oxygen.

b

HIV negative: negative polymerase chain reaction or enzyme-linked immunosorbent assay (ELISA) results, negative maternal test results at enrollment, or absence of evidence to indicate
the child is positive in settings with limited HIV transmission (Bangladesh); HIV positive: detectable viral load or HIV seropositive if >12 months old; HIV-unknown: insufficient evidence to
define HIV status.
c

HIV exposed: HIV positive, positive ELISA results (if < 12 months) or positive maternal history (maternal history must be confirmed by maternal serology for seronegative infants
<7 months); HIV unexposed: (1) documented negative maternal HIV status, (2) <7 months of age with a negative ELISA, or (3) ≥7 months with a negative ELISA result and reported, but
undocumented, negative maternal history; unknown HIV exposure: insufficient evidence to define HIV exposure status.
d

At admission or 24 hours after IS collection or 48 hours after IS collection.

e

Children with >1 IS included in numerator if they received oxygen immediately before either IS procedure.
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Table 2. Serious Adverse Events Reported After Initiating First Induced
Sputum Procedurea in Pneumonia Etiology Research for Child Health
(PERCH) Study Cases

Serious Adverse Event

No.

Risk of Event per
Procedure
(n = 3802), %

Total

13

0.34

Drop in oxygen saturation

9

0.23

New requirement or increased need for
bronchodilator

1

0.03

New onset of unconsciousness or prostration

1

0.03

Death within 4 h of initiating the IS procedure (for
any reason)

2

0.05

Category of relatedness to IS procedure
Definitely

4

0.10

Probably

1

0.03

Possibly

5

0.13

Probably not

3

0.08

Abbreviation: IS, induced sputum.
a

No serious adverse events occurred after the second IS. Table restricted to first induced
sputum procedures to avoid double counting subset of children who underwent a second
IS procedure in denominator.

a procedure for induction of sputum. Of these, 851 patients
had a second procedure, though 92% of these second procedures took place in one site, South Africa. In total there were
4653 procedures. A total of 3362 patients (88%) underwent
an induction of sputum procedure within 24 hours of hospital admission. For the remaining 439 with the first specimen
taken after 24 hours, 337 (77%) had an initial contraindication for the procedure: 102 (23%) had specimen collection
deemed inadvisable by treating clinicians; 71 (16%) had a seizure in the 24 hours before being assessed for the procedure;
64 (15%) had severe bronchospasm; 63 (14%) had oxygen saturation <92%; and 37 (8%) were unable to protect their airway. The remaining 102 (23%) participants had no specified
contraindication.
Thirteen SAEs were reported following the IS procedure, representing a risk of 0.34% per child undergoing the procedure
(0.34% for the first IS and 0.0% for the second IS; Table 2). The
most common SAE (n = 9 [69%]) was a drop in oxygen saturation
that required an increase in the amount of oxygen administered
or the initiation of oxygen administration. The clinical condition
of 8 of these children stabilized within the 4-hour monitoring
period and 1 child stabilized after a longer period (>12 hours).
One child met the SAE criteria for increased need for bronchodilator nebulization. One child experienced a change in level of
consciousness, which was attributed by the safety monitors to a
preexisting condition and not to the procedure itself.
The 13 SAEs included 2 deaths within 4 hours after the procedure. One of these deaths, in a child 5 months of age with very
severe pneumonia who developed severe respiratory distress
2 hours after the IS procedure while breastfeeding and could
not be resuscitated, was categorized as “possibly related” to IS
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collection. Another death was determined to be “probably not
related” and occurred in a 16-month-old child with very severe
pneumonia who was stable for >2 hours after the IS procedure
but suffered a cardiorespiratory arrest during feeding and could
not be resuscitated (Table 3). All but 1 of the SAEs occurred at
some point during the procedure or within 2 hours. Five SAEs
occurred during the procedure, 1 occurred 30 minutes after the
procedure, and 6 more occurred between 30 minutes and 2 hours
post-IS. The single SAE that occurred >2 hours after the procedure is described above as the 16-month-old child who died
during feeding approximately 3.5 hours after IS collection, with
the death being assessed as a likely aspiration event (Table 3).
Children with SAEs were more likely than those without
SAEs to be human immunodeficiency virus (HIV) exposed
(46% of children with SAEs vs 18% of children without an
SAE, P = .018) and to have very severe pneumonia (50% vs
29%, P = .062) (Table 4).
In total, 31 (0.8%) children had the first IS procedure stopped
because of a drop in oxygen saturation below 88% for >60 seconds. An SAE was reported in 4 of these children (see above)
and the study clinician was able to restart the IS procedure for
the remaining 27 children after a period of stabilization (ie, the
child’s respiratory status improved and oxygen saturation was
at least 92% for ≥5 minutes). Of the 851 children undergoing
a second IS procedure, 14 (1.6%) had the procedure stopped
due to a drop in oxygen saturation below 88% for >60 seconds,
and the procedure was reinitiated in all 14. There was no change
in median oxygen requirement before and after the procedure.
Five children (0.5%) required an oxygen increase of >1 L/
minute immediately after the procedure, compared to their
baseline status (Table 5). The percentage of children requiring
supplemental oxygen before the first induced sputum procedure (n = 1091 [29.2%]) dropped to 27.3% (n = 1019) by the
last clinical monitoring time point at 4 hours postprocedure.
There were no differences in consciousness level in the immediate period after the procedure. However, 20 children experienced a decrease in their consciousness level when comparing
immediately before IS and any point during the 4-hour monitoring period after IS. Oxygen saturation remained steady at all
monitoring time points (Table 5). Clinical measures were also
analyzed separately for children who had a second IS, with no
clinically significant changes found in that subset of children
(Supplementary Table 1).
DISCUSSION

The IS procedure was generally well tolerated among a large
and geographically heterogeneous group of children aged
1–59 months, hospitalized with WHO-defined severe or very
severe pneumonia. Serious adverse events were very infrequent
(n= 13 [0.34%]) as were the subset of SAEs that were assessed
as probably, possibly, or definitely related to the IS procedure

Table 3.

Description of Serious Adverse Events Occurring Within 4 Hours of Initiating the Induced Sputum Procedure

Pneumonia
Severity

Age

Sex

Adverse Event

Relatedness

Very
severe

6 mo

F

Drop in oxygen saturation <92% requiring
increased oxygen

Definitely

Approximately 10 min into the procedure, the child’s oxygen saturation dropped
below 92% for >10 min. The child’s clinical status stabilized to stable within an
hour, and the oxygen saturation stabilized at 95%–98% on room air.

Very
severe

2 mo

M New requirement for
bronchodilator

Definitely

During the procedure, child required increased bronchodilator nebulization to stabi- Resolved
lize his oxygen saturation levels, which had been steady on supplemental oxygen
prior to the procedure. Bronchodilators were administered for 15 min, and by 1 h
postprocedure the child was stable, without continuing need for bronchodilators.

Very
severe

23 mo M Drop in oxygen saturation <92% requiring
increased oxygen

Definitely

Child with cyanotic heart disease experienced a drop in measured oxygen
saturation from 96% on room air to 74% while receiving nebulized hypertonic
saline. Oxygen was administered, and the child was clinically stable at 4 h
postprocedure. Study clinicians and the local safety monitor determined that
the preprocedure oxygen saturation levels may have been noted incorrectly
before initiating the IS procedure.

Severe

3 mo

F

Definitely

Resolved
Child experienced an increased oxygen requirement between 30 min and 2 h
postprocedure, and a ward pediatrician recommended a switch from nasal
prong O2 at 2 L/min to a polymask at 10 L/min based on the advice of the
attending physician. By 8 h postprocedure, the child had been weaned back to
nasal prong oxygen and was clinically stable.

Very
severe

3 mo

M Drop in oxygen saturation <92% requiring
increased oxygen

Possibly

A child on supplemental oxygen who had stable clinical signs for 2 hours postResolved
procedure was taken off the ward by a guardian. When study staff located the
child for the 4-h postprocedure clinical monitoring, he was found to have an
oxygen saturation of 80%. Supplemental oxygen was delivered; however, the
child’s guardian continued to remove the oxygen, and the child did not stabilize
until 48 h after the procedure, as oxygen delivery was continuously disrupted.

Severe

1 mo

F

Drop in oxygen saturation <92% requiring
increased oxygen

Possibly

30 min after the IS procedure, the child’s oxygen saturation fell to 90% for >10 min. Resolved
Supplemental oxygen was administered; the child’s clinical status resolved by 4 h
post-IS with an oxygen saturation of 94%–96% on room air.

Severe

8 mo

M Drop in oxygen saturation <92% requiring
increased oxygen

Possibly

Child’s oxygen saturation fell to 95% from 100% and work of breathing increased Resolved
at 30 min post-IS. An attending physician felt the child required intubation at
1–2 h post-IS for increased work of breathing. At 4 h post-IS, the child had
a respiratory rate of 62/min and an oxygen saturation of 98%. The child was
extubated 7 d later.

Severe

3 mo

M Drop in oxygen saturation <92% requiring
increased oxygen

Possibly

Oxygen saturation dropped to 67% from 95% on 2 L/min nasal prong oxygen in a Resolved
child with extensive multilobar pneumonia during the NP aspiration part of the
IS procedure. The procedure was stopped and the oxygen saturation normalized with continued nasal prong oxygen at 2 L/min. At 4 h post-IS, the child had
a respiratory rate of 86/min and 100% oxygen saturation on 12 L/min polymask
oxygen. Over the ensuing several hours the child’s respiratory status deteriorated, with increasing work of breathing and oxygen requirement leading to
intubation 12 h following the procedure. The child self-extubated 6 d later.

Severe

5 mo

F

Possibly

IS collected without event in a child with 98% oxygen saturation on room air.
Death
Postprocedure respiratory rate was 78 breaths/min. During breastfeeding
1 h post-IS, the child developed severe respiratory distress and died despite
resuscitation efforts 2 h after the procedure. The cause of death was assessed
as a likely aspiration event.

Severe

30 mo M Drop in oxygen saturation <92% requiring
increased oxygen

Probably

During the nebulization with hypertonic saline, the child’s oxygen saturation fell to
88%–92%. Low flow oxygen was started and administered for 50 min postprocedure, without attempting to wean the child off oxygen. The child’s oxygen
saturation was >92% at 2 and 4 h postprocedure on room air.

Very
severe

3 mo

M Drop in oxygen satura- Probably
tion <92% requiring
not
increased oxygen

Resolved
Child experienced a seizure 1 h after the IS procedure. The child had a seizure in
the 24 h prior to IS collection, which is a contraindication for the procedure.
However, this was not communicated to the PERCH physician who performed
the IS procedure. The procedure was stopped during the NP suctioning because
of transient desaturation to 80% with O2 saturation returning to 95% within
60 sec of catheter withdrawal. An hour after the IS procedure was started, the
child experienced another seizure. At 4 h after the IS procedure, the child was
alert with an oxygen saturation of 99% on 2 L/min nasal prong oxygen.

Very
severe

16 mo

F

Death

Probably
not

Child with very severe pneumonia and early signs of malnutrition was stable
Death
more than 2 h after specimen collection. Child developed dyspnea while being
fed milk by her father and could not be resuscitated. The cause of death was
assessed as a likely aspiration event.

Very
severe

11 mo

F

New onset of
unconsciousness or
prostration

Probably
not/
unlikely

Child was stable for 1 h after the IS procedure. 90 min after the procedure, the
child developed respiratory distress immediately following feeding. Two contraindications (history of seizure and inability to protect airways) should have
been noted for this case. By 4 h post-IS, the child had oxygen saturation of
85% on room air, which improved to 96% on supplemental oxygen.

Drop in oxygen saturation <92% requiring
increased oxygen

Death

Details

Outcome
Resolved

Diagnosis of
cyanotic
heart
disease

Resolved

Resolved

Abbreviations: IS, induced sputum; NP, nasopharyngeal; O2, oxygen; PERCH, Pneumonia Etiology Research for Child Health.
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Table 4. Characteristics of Cases With and Without a Serious Adverse
Eventa

Characteristics

Cases without
an SAE
(n = 3785b)

Cases with
an SAE
(n = 13)

P Valuec

Site
Kenya

591

15.6

3

23.1

The Gambia

592

15.6

2

15.4

Mali

544

14.4

0

0.0

Zambia

516

13.6

2

15.4
38.5

.99

South Africa

836

22.1

5

Thailand

189

5.0

1

7.7

Bangladesh

517

13.7

0

0.0

1–5 mo

1539

40.7

7

53.8

6–11 mo

858

22.7

3

23.1

12–23 mo

859

22.7

2

15.4

24–59 mo

529

14.0

1

7.7

1587

41.9

7

53.8

.41

504

13.4

3

23.1

.36
.92

Age

Female
Severe malnutritiond

.79

Bronchiolitise

740

19.8

3

23.1

HIV positivef

203

5.4

2

15.4

.24

HIV exposedg

614

17.9

6

46.2

.06

Very severe pneumonia

1081

28.6

7

50.0

.06

Abnormal CXRh

1741

53.0

9

75.0

.20

Data are presented as No. (%).
Abbreviations: CXR, chest radiograph; ELISA, enzyme-linked immunosorbent assay; HIV,
human immunodeficiency virus; PCR, polymerase chain reaction; SAE, serious adverse
event; SD, standard deviation; WHO, World Health Organization.
a

Among children who underwent an induced sputum procedure.

b

This table does not include data for 4 children who had an SAE related to lung aspirates.

c

Calculated from logistic regression (outcome = SAE) adjusted for site and age (site is
adjusted for age only and age is adjusted for site only).
d

WHO weight-for-age z score < –3 SDs.

e

Bronchiolitis reported as admission or discharge diagnoses or concurrent condition.

f

HIV positive: detectable viral load or HIV seropositive if >12 months old.

g
HIV exposed: HIV positive, positive ELISA results (if < 12 months), or positive maternal
history (maternal history must be confirmed by maternal serology for seronegative infants
<7 months).
h

Abnormal chest radiograph defined as presence of consolidation and/or other infiltrate.

(n = 10 [0.26%]). To our knowledge, this is the first large-scale
study that demonstrates a low rate of SAEs with IS collection
in hospitalized children with severe or very severe pneumonia
across multiple settings. This study demonstrates that IS collection can be safely performed in a large sample of children in
typical resource-constrained hospital; however, vigilant monitoring for up to 2 hours postprocedure is necessary.
Our findings are consistent with the low rate of SAEs associated with IS collection shown in other studies among severely
ill children [15–18]. In 2 small case series of children with community-acquired pneumonia in Finland [3] and in 2 PERCH
pilot studies [6, 19], the IS procedure was found to be well tolerated and to produce sputum largely of good quality (defined
as <10 epithelial cells per high-power field) that contained high
frequencies of bacterial and viral pathogens.
Two post-IS deaths reported as SAEs were both temporally associated with reinitiation of feeding following the IS
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procedure. The death that occurred in an infant who reinitiated breastfeeding approximately 2 hours after IS collection was
assessed as “possibly related” to IS collection; 2 site clinicians,
the site safety monitor, and 3 clinicians from the PERCH core
team, including the central safety monitor, could not exclude
that IS collection may have contributed to respiratory distress.
The death that occurred in a toddler during cup feeding approximately 2 hours after IS was assessed as “probably not” related
to IS collection. Following IS collection, it is advisable for a clinician to reassess patients prior to reinitiating feeding to ensure
that the child’s respiratory status is stable enough to tolerate oral
intake.
The relatedness of the reported events to the IS procedure is
difficult to conclude with confidence. All children undergoing
the IS procedure were hospitalized with severe or very severe
pneumonia, and many were severely ill. Distinguishing procedure-related clinical deterioration from the natural history of a
child’s illness is often not possible. It is conceivable that exposing
children with pneumonia to hypertonic saline nebulized solution, while provoking coughing as the intended consequence,
may also in rare circumstances exacerbate the underlying
illness. With the amount of coughing that is induced, respiratory fatigue, aspiration of upper airway secretions, or inadequate respiration could impair the child’s clinical status. Among
the 10 events that were assessed as possibly, probably, or definitely related, 2 of the children required mechanical ventilation
after IS and had prolonged hospital stays.
The clinical respiratory stability of children undergoing the
procedure, as measured by oxygen saturation, oxygen requirement, respiratory rate, and consciousness level, remained
remarkably unaffected by the procedure. Data from some
children who experienced an SAE within the 4 hours following completion of the IS procedure are missing after the time
of the event and not reflected in Table 5. Although this could
bias results toward showing no change from baseline, this is
unlikely to impact the interpretation of results given the small
number of cases for whom data was not available because of
an SAE. The oxygen requirement showed a general decreasing
trend after the procedure and it is possible that IS may benefit
a child with a congested chest as it loosens secretions and may
improve airflow. Our findings suggest that frequent monitoring is useful up to 2 hours following the IS procedure, and that
the PERCH approach was appropriate for the study and may
be of use for implementation as part of clinical care in hospital environments. Because only 1 SAE was detected during the
2- to 4-hour post-IS monitoring period (among 3802 who had
at least 1 IS), hospital resources may best be directed toward
frequent oxygen saturation monitoring up to 2 hours postprocedure. Clinical monitoring data also suggested minimal
differences at the 2- and 4-hour marks for oxygen saturation,
a metric that may be readily assessable in resource-limited
settings.

Table 5. Clinical Measurements in Pneumonia Etiology Research for Child Health (PERCH) Study Cases Before and After First Induced Sputum Procedure
(N = 3736a)
Measurement

Immediately Before

Immediately After

30 Minutes After

2 Hours After

4 Hours After

b

Oxygen flow, L/min
No.
Median (IQR)

1091

1048

1084

1044

1019

2.0 (2.0–2.0)

2.0 (2.0–2.0)

2.0 (2.0–2.0)

2.0 (2.0–2.0)

2.0 (2.0–2.0)

Median change from baseline (IQR)

NA

0

0

0

0

No. (%) with increase of >1 L/min from baseline

NA

5 (0.5)

5 (0.5)

8 (0.7)

8 (0.7)

Oxygen saturation, %
No.
Median (IQR)
Median change from baseline (IQR)
No. (%) on supplemental oxygenc

3349

3340

3347

3336

3324

97 (95–99)

98 (96–99)

97 (95–99)

97 (96–99)

98 (96–99)

NA

0 (–1 to 2)

0 (–1 to 1)

0 (–1 to 1)

0 (–1 to 2)

1091 (32.6)

1048 (31.4)

1084 (32.4)

1044 (31.3)

1017 (30.6)

Respiratory rate, breaths/min
No.
Median (IQR)
Median change from baseline (IQR)
No. (%) tachypneicd

3513

3525

3546

3542

3534

52 (44–60)

54 (46–62)

51 (42–60)

50 (42–58)

48 (40–56)

NA

2 (–2 to 5)

0 (–4 to 3)

–2 (–6 to 2)

–2 (–8 to 1)

2357 (67.1)

2561 (72.7)

2308 (65.1)

2117 (59.8)

1986 (56.2)

Consciousness level (AVPU scale)e
No.
No. (%) V, P, or U
No. (%) with any decrease from baseline

3538

3528

3532

3524

3520

10 (0.3)

10 (0.3)

12 (0.3)

9 (0.3)

7 (0.2)

NA

5 (0.1)

7 (0.2)

4 (0.1)

4 (0.1)

Abbreviations: AVPU, alert, voice, pain, unresponsive; IQR, interquartile range; NA, not applicable (baseline measurement).
a

A total of 66 children had no clinical monitoring data at any time point and have been excluded from this table.

b
c

Among children on supplemental oxygen at respective monitoring time points.

Two children on oxygen at 4 hours postprocedure did not have oxygen saturation data and are not included in the “n” of 1017.

d

Tachypneic: ≥60 breaths per minute (bpm) for children <2 months, ≥50 bpm for children 2–11 months, ≥40 bpm for children 12–59 months.

e

AVPU = alert, voice, pain, unresponsive scale to assess consciousness level. V, P, and U means not alert (A), but responsive to voice (V) or pain (P), or unresponsive (U). Numbers and
percentages for AVPU exclude children whose conscious level was unknown or who were pharmacologically sedated.

The rigorous clinical monitoring done for children in
PERCH throughout the course of the IS specimen collection
provides an opportunity to see the overall clinical effects in a
large and heterogeneous study population of hospitalized children. These findings support IS as a relatively safe procedure
in children with severe pneumonia. Although not statistically
significant, the risk of an SAE after IS collection was higher
among HIV-exposed compared with HIV-unexposed children,
suggesting that a different risk-benefit assessment may apply
to this subset of children. Clinicians caring for children with
severe pneumonia have to consider the safety, feasibility, and
utility of IS, among other factors, when considering whether
the risk of the procedure is warranted. Our analysis addresses
only 1 component of this decision matrix; the utility of IS in
diagnosing the etiology of pneumonia in children is reported
in a companion article [20]. Additional limitations in the study
include potential for practice variation and incomplete monitoring data (Table 2). Despite standardized protocols and twiceyearly refresher training on all study SOPs, local differences
in practice, resources, staffing, and comfort levels with the IS
procedure may have resulted in procedural, monitoring, and
reporting variations.
The collection of an IS specimen was well tolerated in hospitalized children aged 1–59 months with severe or very severe

pneumonia who were eligible for the procedure. Due to the
potential for clinical deterioration, we recommend that clinicians who perform sputum induction in severely ill children
consider implementing a clinical monitoring protocol to identify
and treat any complications that may arise, with close attention
to oxygen saturation levels during and for 2 hours following the
procedure and a clinical assessment before reinitiating feeding.
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